Pharma Surge

Pharma Surge

🇺🇸·18h agoResearch

NCT07638683: A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

Study type: INTERVENTIONAL. Phase: PHASE2.

Publisher

C
ClinicalTrials.gov

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
ClinicalTrials.gov
Region
USA
Scope
Research
Published
August 3, 2026
Language
EN

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

Study type: INTERVENTIONAL. Phase: PHASE2.

Source route

Continue on clinicaltrials.gov

Leave the platform to read the original full article on the publisher site.

Source: ClinicalTrials.gov

Scope: Research

Open original article
NCT07638683: A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). | Pharma Surge